Pharming Group (STU:PHG) Cyclically Adjusted FCF per Share: €0.39 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHG Pharming Group STU:PHG
80 GF Score
Price €10.70
GF Value €12.53
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Cyclically Adjusted FCF per Share?

Pharming Group STU:PHG -1.83% 80 Cyclically Adjusted FCF per Share is €0.39 as of Mar. 2026. GuruFocus rates STU:PHG with a GF Score™ of 80/100 and a GF Value™ of €12.53 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Pharming Group's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.020. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.39 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Pharming Group was 47.70% per year. The lowest was 26.00% per year. And the median was 36.85% per year.

As of today (2026-07-25), Pharming Group's current stock price is €10.70. Pharming Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.39. Pharming Group's Cyclically Adjusted Price-to-FCF of today is 27.44.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharming Group was 66.15. The lowest was 21.82. And the median was 36.00.


Pharming Group  (STU:PHG) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pharming Group's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=10.70/0.39
=27.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Pharming Group was 66.15. The lowest was 21.82. And the median was 36.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Pharming Group Cyclically Adjusted FCF per Share Related Terms


Pharming Group Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Pharming Group's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Cyclically Adjusted FCF per Share Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.20 0.30 0.30 0.39

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.30 0.38 0.39 0.39

STU:PHG vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted Price-to-FCF falls into.


STU:PHG
80GF Score
Pharming Group STU:PHG
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharming Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.02/136.9100*136.9100
=0.020

Current CPI (Mar. 2026) = 136.9100.

Pharming Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.144 100.260 -0.197
201609 -0.088 100.570 -0.120
201612 0.050 100.710 0.068
201703 -0.120 101.440 -0.162
201706 -0.018 101.370 -0.024
201709 0.215 102.030 0.288
201712 0.474 101.970 0.636
201803 -0.027 102.470 -0.036
201806 0.148 103.100 0.197
201809 0.214 103.950 0.282
201812 0.227 103.970 0.299
201903 0.140 105.370 0.182
201906 0.206 105.840 0.266
201909 0.049 106.700 0.063
201912 0.250 106.800 0.320
202003 0.175 106.850 0.224
202006 0.266 107.510 0.339
202009 0.202 107.880 0.256
202012 0.201 107.850 0.255
202103 0.052 108.870 0.065
202106 0.044 109.670 0.055
202109 0.028 110.790 0.035
202112 0.130 114.010 0.156
202203 0.003 119.460 0.003
202206 0.036 119.050 0.041
202209 0.184 126.890 0.199
202212 0.066 124.940 0.072
202303 -0.334 124.720 -0.367
202306 -0.119 125.830 -0.129
202309 0.046 127.160 0.050
202312 0.118 126.450 0.128
202403 -0.109 128.580 -0.116
202406 -0.136 129.910 -0.143
202409 0.163 131.610 0.170
202412 0.121 131.630 0.126
202503 -0.001 133.330 -0.001
202506 0.123 133.960 0.126
202509 0.391 135.920 0.394
202512 0.118 135.270 0.119
202603 0.020 136.910 0.020

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.39 mean?
Pharming Group (STU:PHG) has a Cyclically Adjusted FCF per Share of €0.39 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pharming Group and its competitors.
Is Pharming Group's Cyclically Adjusted FCF per Share too high?
Pharming Group's current Cyclically Adjusted FCF per Share is €0.39. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Pharming Group's Cyclically Adjusted FCF per Share of €0.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Pharming Group and its competitors. Pharming Group's current Cyclically Adjusted FCF per Share is €0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (STU:PHG) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.53, compared to a current price of €10.70 — trading 14.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.39. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Pharming Group (STU:PHG), the current Cyclically Adjusted FCF per Share is €0.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (STU:PHG) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €10.70 is trading 14.6% below its estimated GF Value™ of €12.53. GuruFocus considers Pharming Group to be Modestly Undervalued.

Key valuation signals for STU:PHG:

  • Cyclically Adjusted FCF per Share: €0.39
  • GF Value™: €12.53 vs. price of €10.70 (14.6% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the STU:PHG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for STU:PHG

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.70
Price
€12.53
GF Value